The Ahmedabad based contract research and manufacturing services (CRAMS) company, Dishman Pharmaceuticals has entered into a strategic alliance with a California-based biotech company Codexis.

The Rs. 1000 crore company announced on Thursday that the 5 year alliance would let the Ahmedabad based company use Codexis' proprietary enzymatic bio-catalysis technology in order to manufacture building blocks and intermediates. Reduction of chiral compounds in the APIs and the provision of low-cost, cleaner and greener processes of manufacturing is what the company is looking forward to with this alliance.

High-grade technology platform is something that the Indian pharmaceutical companies had been missing; the 5 year agreement Codexis will make Dishman the first Indian company to have such a platform.

In another announcement, Dishman said that it has raised Rs 75 crore via issuing and allotting secured redeemable non convertible debentures (NCDs).

Codexis Dishman would be the preferred manufacturer and would be able to offer its technology for better manufacturing quality and processes.